|
DEFB1 gene expression and the molecular landscape of colorectal cancer (CRC). |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Caris Life Sciences |
| |
|
Employment - Caris Life Sciences |
| |
|
Employment - Caris Life Sciences |
| |
|
Employment - Caris Life Sciences |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Apple (I) |
Honoraria - Rafael Pharmaceuticals |
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; HalioDx |
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst) |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences |
| |
|
Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Exelixis; Genentech; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical |
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Immunovaccine; Loxo/Lilly; Merck; Novocure; Nucana; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure |
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure |
Research Funding - Intima; Novocure |
Travel, Accommodations, Expenses - GlaxoSmithKline |
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan |
| |
|
Consulting or Advisory Role - Caris Life Sciences; ImaginAb |
Speakers' Bureau - Caris Life Sciences |
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Xencor |
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget |
| |
|
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies |
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Compass Therapeutics; Eisai/H3 Biomedicine; G1 Therapeutics; GlaxoSmithKline; IQvia; Merck; Sorrento Therapeutics; Taiho Pharmaceutical; UpToDate |
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical |
| |
|
Employment - Caris Life Sciences; Indivumed |
|
Honoraria - Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical |
Speakers' Bureau - Amgen; Bayer/Onyx; Merck; Taiho Pharmaceutical |
| |
|
Employment - Caris Life Sciences |
Leadership - Caris Life Sciences |
Stock and Other Ownership Interests - Caris Life Sciences |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche |
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche |
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono |